Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADMA Biologics, Inc. (NASDAQ: ADMA) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated explanations to help interpret the information. ADMA is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases.
Through this page, users can review ADMA’s current and historical SEC filings, including Form 8-K reports that announce material events such as quarterly financial results and business updates. For example, an 8-K dated November 5, 2025, references a press release detailing financial results for the quarter ended September 30, 2025 and a related business update. Filings such as 10-K annual reports and 10-Q quarterly reports (when available) typically contain detailed information on revenue composition, operating segments such as ADMA BioManufacturing and Plasma Collection Centers, risk factors, and descriptions of products like ASCENIV, BIVIGAM and NABI-HB.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand complex regulatory language. Users can also track real-time updates as new filings are posted to the SEC’s EDGAR system, and review insider transaction disclosures on forms such as Form 4 when they are filed, to see reported trades by company officers and directors.
This SEC filings hub is intended for investors and researchers who want a structured view of ADMA’s regulatory reporting, including its financial performance communications, capital structure updates, and disclosures related to its plasma-derived biologics portfolio and manufacturing operations.
ADMA Biologics submitted a Form 144 reporting proposed sales of Common Stock tied to option exercises, all dated
ADMA Biologics director-affiliated funds reported open-market purchases of common stock. Entities associated with director Steve Elms bought a total of 14,000 ADMA shares, with 7,000 shares purchased on March 5, 2026 at a weighted average price of
The filing notes these shares are held by Aisling Capital II LP and Aisling Arcturus Partners, LP, and that Mr. Elms may be deemed a beneficial owner through his roles at Aisling entities while disclaiming beneficial ownership except to the extent of his pecuniary interest. Following these transactions, Aisling-related entities reported 2,045,730 shares, while Mr. Elms also directly holds 87,330 shares and 10,690 restricted stock units that are scheduled to fully vest on
ADMA Biologics President and CEO Adam S. Grossman reported a tax-related share disposition tied to restricted stock unit vesting. On the transaction date, 54,858 shares of common stock were withheld at $15.18 per share to satisfy mandatory tax withholding obligations, and this was explicitly noted as not an open market sale.
After this withholding, Grossman directly owned 2,204,728 shares of ADMA common stock. He also had indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities for which he is disclosed as a control person or managing member.
ADMA Biologics entered a $125 million accelerated share repurchase agreement with JPMorgan Chase Bank as part of its previously authorized $500 million share repurchase program. The company will fund the transaction with borrowings under its existing $225 million revolving credit facility.
ADMA expects to receive about 6.4 million shares of common stock around March 3, 2026, representing roughly 80% of the shares tied to this agreement, based on a closing share price of $15.57 on February 27, 2026. The final share count will depend on the average daily volume‑weighted average price over the ASR term and is expected to be settled within five months, which could result in ADMA receiving additional shares or delivering shares or cash at final settlement.
The company also outlined a 2026 capital return initiative targeting approximately $200 million, noting that, since the program’s May 2025 authorization, prior repurchases plus this ASR represent about $160 million of common stock repurchased. Management highlights sustained revenue growth, expanding margins and anticipated stronger cash flow as support for continuing to invest in growth while returning capital to stockholders.
ADMA Biologics CFO and Treasurer Terry Kohler filed an initial ownership report showing his equity stake in the company. He reported 91,166 stock options and 58,019 shares of common stock held directly. Footnotes explain these reflect previously granted stock options and restricted stock units that vest over four years.
ADMA Biologics is a U.S. biopharmaceutical company focused on plasma-derived therapies for immunodeficient and immune‑compromised patients. It currently markets three FDA‑approved products: ASCENIV, an IVIG for primary humoral immunodeficiency, a second IVIG for PI in adults and children two years and older, and Nabi‑HB for Hepatitis B exposure.
ADMA manufactures at its Boca Raton facility, which it believes can support projected annual revenues greater than
ADMA Biologics reported record fourth quarter and full year 2025 results and announced a CFO transition. Full year 2025 revenue reached $510.2 million, up 20% from 2024, driven largely by ASCENIV, which generated $362.5 million and grew 51% year over year. Gross profit was $292.8 million with a 57.4% margin, while adjusted net income rose to $160.8 million, up 35%, and adjusted EBITDA increased to $231.0 million, up 40%.
Fourth quarter 2025 revenue was $139.2 million, up 18% year over year, with gross profit of $88.8 million and adjusted EBITDA of $73.6 million. ADMA reaffirmed long-term guidance targeting more than $1.1 billion in annual revenue and greater than $700 million in adjusted EBITDA in 2029. The company also highlighted progress on its SG-001 pipeline program and ongoing share repurchases.
Separately, long-time CFO Brad Tade retired effective February 25, 2026 and will serve as a consultant through July 31, 2026, receiving $41,666.67 per month. He is succeeded by Terry (Paul Terence) Kohler, who becomes Chief Financial Officer and Treasurer with a $500,000 base salary, a 45% target bonus opportunity and equity awards subject to multi-year vesting and change-of-control protections.
ADMA Biologics, Inc. executive Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance, reported a Form 4 transaction involving company common stock. On February 19, 2026, 8,161 shares were withheld by the company at $16.32 per share to cover mandatory tax withholding on vesting restricted stock units, which is not an open market sale. After this tax-withholding disposition, she directly held 572,160 shares of common stock, reflecting prior option exercises and earlier RSU net settlements.
ADMA Biologics President and CEO Adam S. Grossman reported a Form 4 transaction where 24,793 shares of common stock were withheld on February 19, 2026 at $16.32 per share to cover mandatory tax obligations upon the vesting of restricted stock units. Footnotes clarify this was a tax-withholding disposition and not an open market sale.
After this transaction, Grossman directly owned 2,259,586 shares of ADMA common stock. He also had indirect ownership of additional shares, including positions held through Areth, LLC and Hariden, LLC, where he is a control person and managing member, respectively.
ADMA Biologics CFO and Treasurer Brad L. Tade reported a tax-related share disposition tied to restricted stock units (RSUs). On the transaction date, 6,479 shares of common stock were withheld by the company at $16.32 per share to satisfy mandatory tax withholding when RSUs vested, and this was not an open market sale. After this withholding, Tade directly owned 232,940 shares of common stock, including multiple blocks of unvested RSUs granted between June 2023 and February 2025 that will settle into shares over time if service conditions are met.